A Phase Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Patients With Previously Untreated Advanced Pancreatic Cancer

Trial Profile

A Phase Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Patients With Previously Untreated Advanced Pancreatic Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Jan 2014

At a glance

  • Drugs Y-90 clivatuzumab tetraxetan (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Immunomedics
  • Most Recent Events

    • 05 Jun 2012 Final results are to be presented at the 59th Annual Meeting of the Society of Nuclear Medicine, according to an Immunomedics media release.
    • 04 Jun 2012 Final and updated survival results have been presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO-2012), according to an Immunomedics media release. Results were also summarised in the media release.
    • 25 May 2012 Final results are to be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO-2012), according to an Immunomedics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top